56-53-1RGLYKWWBQGJZGM-ISLYRVAYSA-NRGLYKWWBQGJZGM-ISLYRVAYSA-N
DiethylstilbestrolDES
Phenol, 4,4'-[(1E)-1,2-diethyl-1,2-ethenediyl]bis-
(E)-3,4-Bis(4-hydroxyphenyl)-3-hexene
(E)-4,4'-(1,2-Diethyl-1,2-ethenediyl)bisphenol
(E)-Diethylstilbestrol
4,4'-Dihydroxydiethylstilbene
4,4'-Dihydroxy-α,β-diethylstilbene
4,4'-Stilbenediol, α,α'-diethyl-, (E)-
4,4'-Stilbenediol, α,α'-diethyl-, trans-
Agostilben
Antigestil
Bertrol
Bio-des
Comestrol
Cyren A
Dawe's destrol
DiBestrol 2 Premix
Di-Estryl
Diethylstilbesterol
dietilestilbestrol
Distilbene
Domestrol
Estilbin MCO
Estrobene
Estromenin
Estrosyn
Fonatol
Grafestrol
Hi-Bestrol
Iscovesco
Menostilbeen
Microest
Milestrol
Neo-Oestranol I
NSC 3070
Oestrogenine
Oestromenin
Oestromensyl
Oestromon
Pabestrol
Palestrol
Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)-
Rumestrol 1
Rumestrol 2
Sexocretin
Stilbestrol
Stilbetin
Stilboefral
Stilboestroform
Stilboestrol
Stilkap
Stil-Rol
Synestrin
Synthoestrin
Synthofolin
Syntofolin
trans-4,4'-Dihydroxy-α,β-diethylstilbene
trans-Diethylstilbestrol
trans-α,α'-Diethyl-4,4'-stilbenediol
Vagestrol
α,α'-Diethyl-4,4'-stilbenediol
α,α'-Diethylstilbenediol
DTXSID3020465446-72-0TZBJGXHYKVUXJN-UHFFFAOYSA-NTZBJGXHYKVUXJN-UHFFFAOYSA-N
GenisteinGEN
4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-hydroxyphenyl)-
5,7,4'-Trihydroxyisoflavone
5,7-dihidroxi-3-(4-hidroxifenil)-4-benzopirona
5,7-Dihydroxy-3-(4-hydroxyphenyl)-4-benzopyron
5,7-Dihydroxy-3-(4-hydroxyphenyl)-4-benzopyrone
Baichanin A
Bonistein
Genisteol
Genisterin
Isoflavone, 4',5,7-trihydroxy-
NSC 36586
Prunetol
Sophoricol
4',5,7-Trihydroxyisoflavone
DTXSID5022308PR:000007204estrogen receptorPR:000027727estrogen receptor alpha complexPR:000014896homeobox protein SIX1CL:0000646basal cellD008679MetaplasiaCL:0000150glandular epithelial cellD018196adenosquamous carcinomaGO:0030284estrogen receptor activityGO:0030520intracellular estrogen receptor signaling pathwayGO:0010467gene expressionGO:0008283cell proliferationD006965hyperplasia1increased8morphological changeDiethylstilbestrol2016-11-29T18:42:272016-11-29T18:42:27Genistein2016-11-29T18:42:262016-11-29T18:42:2610090mouseprepubertal increase, Estrogen receptor (ER) activityprepubertal increase, Estrogen receptor (ER) activityMolecular2016-11-29T18:41:292016-12-03T16:37:53Activation, estrogen receptor alphaActivation, estrogen receptor alphaMolecular2016-11-29T18:41:292016-12-03T16:37:53Promotion, SIX-1 postive basal-type progenitor cellsPromotion, SIX-1 postive basal-type progenitor cellsCellularCL:0000646basal cell2016-11-29T18:41:292017-09-16T10:17:09Proliferation/Clonal Expansion, aberrant basal cellsProliferation/Clonal Expansion, aberrant basal cellsCellularCL:0000646basal cell2016-11-29T18:41:292017-09-16T10:17:10squamous metaplasia, aberrant basal cellssquamous metaplasia, aberrant basal cellsTissue2016-11-29T18:41:292016-12-03T16:37:53Increased, Hyperplasia (glandular epithelial cells of endometrium)Increased, Hyperplasia (glandular epithelial cells of endometrium)CellularCL:0000150glandular epithelial cell2016-11-29T18:41:292017-09-16T10:17:10Increased, adenosquamous carcinomas of endometriumIncreased, adenosquamous carcinomas of endometriumTissueUBERON:0001295endometrium2016-11-29T18:41:292017-09-16T10:17:10c6696b96-bda3-44e9-b03d-83346bb3dd6358ccd3b8-295b-4a46-a7a3-6c64d237cbec2016-11-29T18:41:362016-12-03T16:38:0358ccd3b8-295b-4a46-a7a3-6c64d237cbec8a3d70fd-fbf3-4b5f-8dac-a0618128faf62016-11-29T18:41:362016-12-03T16:38:038a3d70fd-fbf3-4b5f-8dac-a0618128faf6910a62a1-b7dc-4fb5-b04f-4eedf86888de2016-11-29T18:41:362016-12-03T16:38:03910a62a1-b7dc-4fb5-b04f-4eedf86888dec559f60a-8e21-420f-8f20-97292f10b7942016-11-29T18:41:362016-12-03T16:38:03c559f60a-8e21-420f-8f20-97292f10b794fca983d2-1a67-4c76-9993-3989b59b44892016-11-29T18:41:362016-12-03T16:38:03fca983d2-1a67-4c76-9993-3989b59b4489f1f3f419-7c41-4e1f-bcab-e9afb1e0d74e2016-11-29T18:41:362016-12-03T16:38:03Early-life estrogen receptor activity leading to endometrial carcinoma in the mouse.Early onset ER activity and endometrial carcinoma<p>Cancer AOP Workgroup. National Health and Environmental Effects Research Laboratory, Office of Research and Development, Integrated Systems Toxicology Division, US Environmental Protection Agency, Research Triangle Park, NC. Corresponding author for wiki entry (wood.charles@epa.gov)</p>
Under Development: Contributions and Comments WelcomeUnder Development1.29<p>This putative adverse outcome pathway (AOP) outlines potential key events leading to a tumor outcome in standard carcinogenicity models. This information is based largely on modes of action described previously in cited literature sources and is intended as a resource template for AOP development and data organization. Presentation in this Wiki does not indicate EPA acceptance of a particular pathway for a given reference agent, only that the information has been proposed in some manner. In addition, this putative AOP relates to the model species indicated and does not directly address issues of human relevance.</p>
adjacentNot SpecifiedHighadjacentNot SpecifiedHighadjacentNot SpecifiedHighadjacentNot SpecifiedHighnon-adjacentNot SpecifiedHighnon-adjacentNot SpecifiedHighHighFemaleModerateFetal to ParturitionModerateJuvenileHighNot SpecifiedNot Specified<p>1. Klaunig, J. E., Babich, M. A., Baetcke, K. P., Cook, J. C., Corton, J. C., David, R. M., DeLuca, J. G., Lai, D. Y., McKee, R. H., Peters, J. M., Roberts, R. A., and Fenner-Crisp, P. A. (2003). PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Critical reviews in toxicology 33(6), 655-780, 10.1080/713608372.</p>
<p>2. Newbold, R. R., Banks, E. P., Bullock, B., and Jefferson, W. N. (2001). Uterine adenocarcinoma in mice treated neonatally with genistein. Cancer research 61(11), 4325-8.</p>
<p>3. Suen, A. A., Jefferson, W. N., Wood, C. E., Padilla-Banks, E., Bae-Jump, V. L., and Williams, C. J. (2016). SIX1 Oncoprotein as a Biomarker in a Model of Hormonal Carcinogenesis and in Human Endometrial Cancer. Molecular cancer research : MCR doi: 10.1158/1541-7786.MCR-16-0084, 10.1158/1541-7786.MCR-16-0084.</p>
2016-11-29T18:41:172023-04-29T16:02:58